XRAY Q3 2026 Earnings Presentation vFINAL

November 5, 2026

Third Quarter 2026 Earnings Conference Call

Hosted DS World events with a 60% increase in workshops, lectures and hands-on CE courses versus prior year

Updating FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30

• Seven new distribution agreements signed YTD

• Simplified incentive structure and inventory model enabling operational efficiencies

• Driving growth through mutually beneficial relationships

  Broadening Access to Capital Equipment

• Expanding commercial reach across North America and key regional markets

• Supporting practices to optimize workflows

• Enabling practices to deliver single-visit dentistry

Building U.S. Momentum to Support Return-to-Growth

Stronger field coverage and capabilities are supporting early commercial gains

Mid-single digits

Quota-carrying field vacancies, down from approximately 20%

Recruit & Retain

Improved significantly; attracting talent to

further stabilize sales teams

MIS certification

MIS sales force to be certified by end of year

100% certified

Premium implant sales force certification completed

More conversions

September MIS conversions increased sharply versus the historical monthly pace

Double-digit

U.S. MIS sales growth in Q3 versus prior year

Building on MIS momentum to deliver more consistent performance across the portfolio

6×

increase YoY

Clinical education investment

>60%

Increase YoY

Implants education engagements

>160

Endo courses in H2

Launch of high-impact, hands-on programs in North America

Executing a step-change in clinical education investment in North America

Learning formats

Hands-on

Lectures

Virtual

Rep-led training

University events

Partner events

Symposia & summits

Sales training and clinical education are supporting early gains in adoption and sales

SALES MOMENTUM ADOPTION & CUSTOMER ENGAGEMENT

Continued year-over-year growth, with total file sales also increasing.

Reorder rates improved consistently throughout the year.

Focus brands returned to growth; Cercon 4D added incremental sales.

Sell-out outpaced sell-in across Restorative and Preventive; new customer retention improved.

Americas sales grew year over year.

Conversions accelerated in September versus the historical monthly pace.

Focused commercial investment • Improving adoption • Building more consistent growth

Completed Launch of Wellspect SurityTM Portfolio in the U.S.

y

• Surit female external catheter launches with ease of use, discretion, and user comfort

• Launched January 2026

• Surit male external catheter builds on expanding portfolio of incontinence management solutions

  y

• Launched April 2026

• Surit Urinary Management System, a discreet at-home urine collection device

  y

• Launched August 2026

• Surit portfolio, may be covered by traditional Medicare for eligible beneficiaries when medically necessary

  y

• Important step in expanding access and reducing barriers to at-home management

• Announced October 2026

  Increased investment 15% YoY to further penetrate Urine Management market

  Transformation Office Shifting from Stabilization to Value Creation

  Standardize and Automize Workflows

  Scale transactional work and capabilities

  03

  Procure-to-Pay

  Increase spend control, standardization and process automation

  02

  Quote-to-Cash

  Simplify pricing, ordering, fulfillment, billing and collections

  01

  Simplification Cost, process and organizational

  complexity addressed

  with urgency

  ✓

  • U.S. Growth Focus

  Commercial actions prioritized around the largest growth engine

  Funding the reset and establishing stronger cost discipline

  Operating Mechanism Transformation Office, governance and

  accountability

  embedded

  ✓

  ~$120M

  savings initiative in 2026

  Stabilizing the Business

  Scale the Model

  Target: lower SG&A, improved cash conversion and a more consistent customer experience

10

Q3 2026

Q3 2025

YoY

Net Sales

$836M

$904M

(7.6%)

Operating Cash Flow

$32M

$79M

(59.5%)

11 Commentary and trends are based on as reported vs. Q3 2025 unless otherwise noted

Constant currency, adjusted EBITDA, adjusted EBITDA %, and adjusted EPS are Non-GAAP measures as defined on slide 15

Net Sales

As Reported

Constant Currency

Commentary

$230M

(11.0%)

(10.1%)

• CAD/CAM: Lower volumes in Americas driven by the planned shift in distributor inventory model

• Equipment & Instruments: Lower volumes of Imaging products globally, partially offset by Instruments growth in EMEA and Americas

  • Decline driven by lower volumes of Endo products in EMEA and unfavorable pricing, partially offset by higher volumes of Endo files and Restorative blocks in the U.S.

  (3.6%)

  (4.0%)

  $343M

  Essential Dental Solutions

  (EDS)

$171M

(16.6%)

(16.2%)

• Orthodontics: Decline attributable to ($12M) Byte YoY impact and lower volumes in the U.S., partially offset by mid-single digit growth in EMEA

• Implants & Prosthetics: Lower premium implant volumes across all regions, partially offset by DD growth for value implants in the U.S.

14

Constant Currency

Reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

Adjusted Operating Income and Margin

Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales.

• Business combination-related costs: costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.

• Restructuring-related charges and other costs: costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.

• Goodwill and intangible asset impairments: include charges related to goodwill and intangible asset impairments.

• Amortization of purchased intangible assets: includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.

• Fair value and credit risk adjustments: include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments.

Adjusted Gross Profit and Margin

Gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales. Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.

Adjusted Net Income (Loss)

Net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above and the related income tax impacts of those items, as well as the tax effects of certain significant and discrete tax adjustments, including benefits and provisions related to changes in realization of deferred tax assets and tax credit carryforwards, as well as other events that affect comparability and are not core to our underlying operational performance.

Adjusted EBITDA and Margin

In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

Adjusted Earnings (Loss) Per Diluted Share

Computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.

Free Cash Flow

Net cash provided by operating activities minus capital expenditures during the same period.

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations

Adjusted EBITDA

20